Login
$XFOR
$2.84 +$0.01 (0.35%) After hours

$XFOR 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Other Events

Virtual Investor Day October 29, 2026 Nasdaq: XFOR Exhibit 99.1

08 Oct 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +3 more

- Strengthens Financial Flexibility with Access to Funding for Corporate and Commercial Activities -

09 Sep 2026 8-K: Other Events

Corporate Presentation September 2026 Nasdaq: XFOR EXHIBIT 99.1

08 Sep 2026 8-K: Other Events

- FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial -

01 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BOSTON, July 1, 2026 – X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced the appointment of Kelly Gold to the Company’s Board of Directors effective July ...

12 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The purpose of this Second Amended and Restated 2017 Equity Incentive Plan (the “Plan”) of X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Compa...

05 Nov 2025 8-K: Results of Operations and Financial Condition

Company’s strategic focus and highest priority is now the advancement of the 4WARD Phase 3 chronic neutropenia trial

27 Oct 2025 8-K: Entry into a Material Definitive Agreement

Pre-Funded Warrants to Purchase 700,000 Shares of Common Stock

17 Sep 2025 8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more

Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M

25 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 Aug 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 12, 2025 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (...

12 Aug 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 11, 2025 by and among X4 Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (...

23 Jun 2025 8-K: Entry into a Material Definitive Agreement

THIS PURCHASE AGREEMENT (the "Agreement"), dated as of June 23, 2025, is made by and between X4 PHARMACEUTICALS, INC., a Delaware corporation (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the...

11 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2025, X4 Pharmaceuticals Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”), at which a quorum was present. The final results for each of the proposals submitted to a vote of the Company’s stoc...

01 May 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026

24 Apr 2025 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

CERTIFICATE OF AMENDMENTTORESTATED CERTIFICATE OF INCORPORATIONOFX4 PHARMACEUTICALS, INC.

18 Apr 2025 8-K: Submission of Matters to a Vote of Security Holders

On April 17, 2025, X4 Pharmaceuticals, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) at 8:00 a.m. Eastern Time for the purposes of considering and voting upon the proposals below. As of the record da...

25 Mar 2025 8-K: Results of Operations and Financial Condition

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites;

03 Mar 2025 8-K: Other Events

As previously disclosed on a Current Report on Form 8-K filed by X4 Pharmaceuticals, Inc. (the “Company”), on August 13, 2024, the Company received a deficiency letter (the “Nasdaq Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) not...

06 Feb 2025 8-K: Costs Associated with Exit or Disposal Activities; Regulation FD Disclosure

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support